Invivyd Appoints William Duke as Chief Financial Officer
05 September 2023 - 9:00PM
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical
company on a mission to protect the vulnerable from serious viral
infectious diseases, today announced the appointment of William
Duke as Chief Financial Officer. Mr. Duke will lead Invivyd’s
financial strategy to support the company’s continued growth. Mr.
Duke has more than 25 years of finance, accounting, and operations
experience, including over a decade of senior leadership experience
in the biotechnology industry.
“Bill’s wealth of financial leadership experience will be
invaluable as the company continues to plan for the rapid
initiation of a pivotal clinical study, a potential EUA submission,
and a potential launch of VYD222,” said Dave Hering, Chief
Executive Officer of Invivyd. “With his demonstrated success
leading initiatives that have fueled the advancement of novel
therapeutics and led to significant value creation for
shareholders, I’m thrilled to welcome Bill to our executive
leadership team as we continue to rapidly advance our mission.”
“I’m delighted to join Invivyd at such an exciting time for the
company,” said William Duke, Chief Financial Officer of Invivyd. “I
look forward to leveraging my experience to support the development
of VYD222, as well as Invivyd’s work to establish a pipeline of
engineered monoclonal antibody candidates that can be deployed in
the future to keep pace with viral evolution and provide vulnerable
people with protection from viral threats.”
Prior to joining Invivyd, Mr. Duke served as the Chief Financial
Officer of Apexigen, Inc. where he was responsible for all areas of
finance and accounting and helped guide the company through its
sale to Pyxis Oncology, Inc. Before Apexigen, he was Chief
Financial Officer of Kaleido Biosciences, Inc., where he led the
successful completion of multiple financings. Prior to Kaleido
Biosciences, he was Chief Financial Officer of Pulmatrix, Inc.,
where he helped negotiate the company’s first product partnership
and led the successful completion of several public offerings.
Prior to that, he held senior financial leadership roles at
Valeritas, Inc. and Genzyme Corporation, where he helped in the
sale of the company to Sanofi. Mr. Duke is a certified public
accountant and holds a B.S. in Business Administration from
Stonehill College and an M.B.A. from Bentley College.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a
mission to rapidly and perpetually deliver antibody-based therapies
that protect vulnerable people from the devastating consequences of
circulating viral threats, beginning with SARS-CoV-2. Invivyd’s
technology works at the intersection of evolutionary virology,
predictive modeling, and antibody engineering, and is designed to
identify high-quality, long-lasting antibodies with the potential
to resist viral escape. The company is generating a robust pipeline
of product candidates which could be used in prevention or
treatment of serious viral diseases, starting with COVID-19 and
expanding into influenza and other high-need indications. Visit
https://invivyd.com/ to learn more.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “anticipates,” “believes,” “could,” “expects,”
“intends,” “potential,” “projects,” and “future” or similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. Forward-looking statements
include statements concerning, among other things, the company’s
ongoing research and clinical development plans and the timing
thereof, including with respect to advancing its lead candidate,
VYD222; the company’s plan for the rapid initiation of a pivotal
clinical study, a potential emergency use authorization (EUA)
submission, and a potential launch of VYD222; the company’s efforts
to establish a pipeline of engineered monoclonal antibody
candidates that can be deployed in the future to keep pace with
viral evolution and provide vulnerable people with protection from
viral threats; the company’s ability to rapidly and perpetually
deliver antibody-based therapies that protect vulnerable people
from the devastating consequences of circulating viral threats,
beginning with SARS-CoV-2; the potential for the company’s product
candidates to be high-quality, long-lasting antibodies with the
potential to resist viral escape; the company’s plans to generate a
robust pipeline of product candidates which, if authorized or
approved, could be used in prevention or treatment of serious viral
diseases, starting with COVID-19 and expanding into influenza and
other high-need indications; and other statements that are not
historical fact. The company may not actually achieve the plans,
intentions or expectations disclosed in the company’s
forward-looking statements and you should not place undue reliance
on the company’s forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause the
company’s actual results to differ materially from the results
described in or implied by the forward-looking statements,
including, without limitation: the ability to gain complete
alignment with the applicable regulatory authorities on the
clinical trial design and development pathway for VYD222, including
the use of an immunobridging pathway in the U.S., and the timing
thereof; the timing and progress of the company’s discovery,
preclinical and clinical development activities, including the
company’s ability to rapidly initiate a VYD222 pivotal clinical
trial; the company’s ability to generate and utilize tools to
discover and develop a pipeline of antibodies to treat current and
potential future SARS-CoV-2 variants; the impacts of the COVID-19
pandemic on the company’s business and those of its collaborators,
the company’s clinical trials and its financial position;
unexpected safety or efficacy data observed during preclinical
studies or clinical trials; the predictability of clinical success
of VYD222 or other product candidates based on neutralizing
activity in preclinical studies; the risk that results of
preclinical studies or clinical trials may not be predictive of
future results in connection with current or future clinical
trials; variability of results in models used to predict activity
against SARS-CoV-2 variants of concern; clinical trial site
activation or enrollment rates that are lower than expected;
changes in expected or existing competition; changes in the
regulatory environment; the uncertainties and timing of the
regulatory approval process; whether VYD222 or any other product
candidate or combination of candidates is able to demonstrate and
sustain neutralizing activity against predominant SARS-CoV-2
variants, particularly in the face of viral evolution; whether the
company’s product candidates will be high-quality, long-lasting
antibodies that resist viral escape; whether the company is able to
successfully submit an EUA in the future, and the outcome of any
such EUA submission; whether the company’s research and development
efforts will identify and result in safe and effective therapeutic
options for infectious diseases other than COVID-19; and whether
the company has adequate funding to meet future operating expenses
and capital expenditure requirements. Other factors that may cause
the company’s actual results to differ materially from those
expressed or implied in the forward-looking statements in this
press release are described under the heading “Risk Factors” in the
company’s Annual Report on Form 10-K for the year ended December
31, 2022 filed with the Securities and Exchange Commission (SEC),
and in the company’s other filings with the SEC, and in its future
reports to be filed with the SEC and available at www.sec.gov. Such
risks may be amplified by the impacts of the COVID-19 pandemic.
Forward-looking statements contained in this press release are made
as of this date, and Invivyd undertakes no duty to update such
information whether as a result of new information, future events
or otherwise, except as required under applicable law.
This press release contains hyperlinks to information that is
not deemed to be incorporated by reference in this press
release.
Contacts:
Scott Young(781) 208-1747syoung@invivyd.com
Gabriella Linville-Engler(781)
208-0160gengler@invivyd.com
Invivyd (NASDAQ:IVVD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Invivyd (NASDAQ:IVVD)
Historical Stock Chart
From Sep 2023 to Sep 2024